Biogen/Eisai Alzheimer’s Drug Wins Full FDA Approval
- Posted by ISPE Boston
- On July 13, 2023
The FDA has granted full approval to Leqembi, the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer’s disease (AD). According to Eisai, which developed the drug with Biogen, Leqembi could generate $7 billion in annual sales globally by 2030. […]
Read More